

February 7, 2020

**VIA EDGAR**

U.S. Securities and Exchange Commission  
Division of Corporation Finance  
100 F. Street, N.E.  
Washington, DC 20549

Re: **Can-Fite BioPharma Ltd.  
Registration Statement on Form F-1 (File No. 333-236064)  
Concurrence in Acceleration Request**

Ladies and Gentlemen:

H.C. Wainwright & Co., LLC ("Wainwright"), as placement agent for the referenced offering, hereby concurs in the request by Can-Fite BioPharma Ltd. that the effective date of the above-referenced registration statement be accelerated to 9:00 a.m. (Eastern Time), or as soon as practicable thereafter, on February 10, 2020, pursuant to Rule 461 under the Securities Act. Wainwright affirms that it is aware of its obligations under the Securities Act in connection with this offering.

**H.C. WAINWRIGHT & CO., LLC**

By: /s/ Edward D. Silvera  
Name: Edward D. Silvera  
Title: Chief Operating Officer